543-The Landscape of KRAS Inhibitors in Cancer Treatment

The paper details the evolving therapeutic landscape of targeting the RAS gene family, a critical oncogenic driver found in roughly 20% of human cancers. While long considered undruggable, recent scientific breakthroughs have led to the development of mutation-specific inhibitors like sotorasib and adagrasib, which primarily target the KRAS G12C mutation. The sources explore the complex biochemica...去小宇宙查看完整单集简介
前往小宇宙评论区与主播互动